Characterizing the willingness to undergo treatment in patients with alopecia areata

被引:0
|
作者
Lauren F. O’Connor
Kristen M. Wells
机构
[1] University of Virginia,School of Medicine, Department of Public Health Sciences
来源
Archives of Dermatological Research | 2022年 / 314卷
关键词
Alopecia areata; Hair; Patient needs; Treatment; Burden; Side effects; Hair regrowth; Treatment administration; Survey;
D O I
暂无
中图分类号
学科分类号
摘要
Alopecia areata is an autoimmune disease that results in partial or total balding of the scalp and/or body. Treatments available are minimally effective, have severe side effects, and are often painful. Given these burdens, patients may not feel undergoing treatment is worthwhile. The purpose of this study is to characterize the willingness of patients with alopecia areata to undergo treatment. We found that few patients are willing to undergo treatment at the risk of severe health side effects. The most acceptable form of treatment administration was topical and the least acceptable was injection at the site of hair loss. A majority of patients would only undergo treatment for hair growth that is cosmetically acceptable and the most important site of hair regrowth was the scalp. The willingness to undergo treatment differed significantly by gender, age, time since disease onset, and disease severity. This study offers insight into the preferences of patients with alopecia areata and characteristics that would make treatment widely acceptable. Institutions conducting research on treatment for alopecia areata can use the results of this study to better understand the needs of their target population.
引用
收藏
页码:749 / 757
页数:8
相关论文
共 50 条
  • [1] Characterizing the willingness to undergo treatment in patients with alopecia areata
    O'Connor, Lauren F.
    Wells, Kristen M.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2022, 314 (08) : 749 - 757
  • [2] Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis
    Coronel-Perez, I. M.
    Rodriguez-Rey, E. M.
    Camacho-Martinez, F. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (04) : 481 - 485
  • [3] Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
    Faria, Sofia
    Freitas, Egidio
    Torres, Tiago
    DRUGS IN CONTEXT, 2023, 12
  • [4] Aproaches in the treatment of alopecia areata
    Aktas, Ekrem
    Aykol, Deniz
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2005, 39 (01): : 20 - 27
  • [5] Platelet-rich plasma in the treatment of alopecia areata: A retrospective evaluation of 17 patients
    Kelleci, Yusuf
    Aydin, Fatma
    Sahin, Gokhan
    Yuksel, Esra Pancar
    DERMATOLOGICA SINICA, 2023, 41 (02) : 111 - 115
  • [6] A Practical Approach to the Treatment of Alopecia Areata
    Dhurat, Rachita
    Sharma, Richa
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2022, 13 (06) : 725 - 728
  • [7] New aspects of the treatment of alopecia areata
    Brzezinska-Wcislo, Ligia
    Bergler-Czop, Beata
    Wcislo-Dziadecka, Dominika
    Lis-Swiety, Anna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2014, 31 (04): : 262 - 265
  • [8] Dermoscopic Findings of Patients with Alopecia Areata
    Kayikci, Mubeccel Alkurt
    Arican, Ozer
    TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2012, 32 (04): : 1064 - 1071
  • [9] Evaluation of Treatment Response by Using a Handheld Dermoscope in Patients with Alopecia Areata
    Kose, Ozlem Karadag
    Gulec, A. Tulin
    TURK DERMATOLOJI DERGISI-TURKISH JOURNAL OF DERMATOLOGY, 2018, 12 (03): : 143 - 148
  • [10] Oral tofacitinib for the treatment of alopecia areata in pediatric patients
    Kibbie, Jon
    Kines, Kelsey
    Norris, David
    Dunnick, Cory A.
    PEDIATRIC DERMATOLOGY, 2022, 39 (01) : 31 - 34